ArticleCirculation research2011
Reprogramming of skeletal myoblasts for induction of pluripotency for tumor-free cardiomyogenesis in the infarcted heart.
Article in Circulation research, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 103 citations in OpenAlex.
- Perspective on Stem Cell Therapy in Organ Fibrosis: Animal Models and Human Studies.Life (Basel, Switzerland) · 2021Review
- Adenine acts in the kidney as a signaling factor and causes salt- and water-losing nephropathy: early mechanism of adenine-induced renal injury.American journal of physiology. Renal physiology · 2019Article
- iPS-Cell Technology and the Problem of Genetic Instability-Can It Ever Be Safe for Clinical Use?Journal of clinical medicine · 2019Review
- The impact of in vitro cell culture duration on the maturation of human cardiomyocytes derived from induced pluripotent stem cells of myogenic origin.Cell transplantation · 2018Article
- Therapeutic Use of Stem Cells for Myocardial Infarction.Bioengineering (Basel, Switzerland) · 2018Review
- New strategies for improving stem cell therapy in ischemic heart disease.Heart failure reviews · 2016Review
- The Promise and Challenge of Induced Pluripotent Stem Cells for Cardiovascular Applications.JACC. Basic to translational science · 2016Article
- Generation of electrophysiologically functional cardiomyocytes from mouse induced pluripotent stem cells.Stem cell research · 2016Article
- Attenuation of teratoma formation by p27 overexpression in induced pluripotent stem cells.Stem cell research & therapy · 2016Article
- Blockade of senescence-associated microRNA-195 in aged skeletal muscle cells facilitates reprogramming to produce induced pluripotent stem cells.Aging cell · 2016Article
- MicroRNA-150 protects the mouse heart from ischaemic injury by regulating cell death.Cardiovascular research · 2015Article
- Induced pluripotent stem cells for post-myocardial infarction repair: remarkable opportunities and challenges.Circulation research · 2014Review
- Proteomic profiling of cardiac tissue by isolation of nuclei tagged in specific cell types (INTACT).Development (Cambridge, England) · 2014Article
- Article
- Article
- Enhanced mesenchymal stem cell survival induced by GATA-4 overexpression is partially mediated by regulation of the miR-15 family.The international journal of biochemistry & cell biology · 2013Article
- Let-7 in cardiovascular diseases, heart development and cardiovascular differentiation from stem cells.International journal of molecular sciences · 2013Review
- The functions of microRNAs and long non-coding RNAs in embryonic and induced pluripotent stem cells.Genomics, proteomics & bioinformatics · 2013Review
- Human kidney cell reprogramming: applications for disease modeling and personalized medicine.Journal of the American Society of Nephrology : JASN · 2013Review
- Sources for skeletal muscle repair: from satellite cells to reprogramming.Journal of cachexia, sarcopenia and muscle · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
rationaleSkeletal myoblasts (SMs) with inherent myogenic properties are better candidates for reprogramming to pluripotency.
objectiveTo reprogram SMs to pluripotency and show that reprogrammed SMs (SiPS) express embryonic gene and microRNA profiles and that transplantation of predifferentiated cardiac progenitors reduce tumor formation. METHODS AND
resultsThe pMXs vector containing mouse cDNAs for Yamanaka's quartet of stemness factors were used for transduction of SMs purified from male Oct4-GFP(+) transgenic mouse. Three weeks later, GFP(+) colonies of SiPS were isolated and propagated in vitro. SiPS were positive for alkaline phosphatase, expressed SSEA1, and displayed a panel of embryonic stem (ES) cell-specific pluripotency markers. Embryoid body formation yielded beating cardiomyocyte-like cells, which expressed early and late cardiac-specific markers. SiPS also had an microRNA profile that was altered during their cardiomyogenic differentiation. Noticeable abrogation of let-7 family and significant up-regulation of miR-200a-c was observed in SiPS and SiPS-derived cardiomyocytes, respectively. In vivo studies in an experimental model of acute myocardial infarction showed extensive survival of SiPS and SiPS-derived cardiomyocytes in mouse heart after transplantation. Our results from 4-week studies in DMEM without cells (group 1), SMs (group-2), SiPS (group-3), and SiPS-derived cardiomyocytes (group 4) showed extensive myogenic integration of the transplanted cells in group 4 with attenuated infarct size and improved cardiac function without tumorgenesis.
conclusionsSuccessful reprogramming was achieved in SMs with ES cell-like microRNA profile. Given the tumorgenic nature of SiPS, their predifferentiation into cardiomyocytes would be important for tumor-free cardiogenesis in the heart.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.